PT - JOURNAL ARTICLE AU - Danielle Dias Conte AU - Joseane Mayara Almeida Carvalho AU - Luciano Kleber de Souza Luna AU - Klinger Soares Faíco-Filho AU - Ana Helena Perosa AU - Nancy Bellei TI - Comparative analysis of point-of-care lateral flow immunoassays for the detection of IgM and IgG anti-SARS-CoV-2 antibodies in healthcare workers AID - 10.1101/2020.11.11.20229914 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.11.20229914 4099 - http://medrxiv.org/content/early/2020/11/12/2020.11.11.20229914.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.11.11.20229914.full AB - Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days after symptoms (DAS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum samples. Bioclin was more sensitive (p<0.01), regardless of the DAS. Thus, the Bioclin can be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJ.M.A.C. and L.K.S.L. are fellows of the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil. D.D.C. is a fellow of the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sao Paulo hospital Research Ethics Committee (CEP n. 34371020.5.0000.5505).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article